Relationship of treatment-related cytopenias and response to lenalidomide in patients with lower-risk myelodysplastic syndromes.
about
Short- and long-term benefits of lenalidomide treatment in patients with lower-risk del(5q) myelodysplastic syndromesA phase 2 study of high-dose lenalidomide as initial therapy for older patients with acute myeloid leukemia.The clinical safety of lenalidomide in multiple myeloma and myelodysplastic syndromes.A randomized, double-blind, placebo-controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate-1 risk myelodysplastic syndrome receiving lenalidomide.Lenalidomide: a review of its use in patients with transfusion-dependent anaemia due to low- or intermediate-1-risk myelodysplastic syndrome associated with 5q chromosome deletion.Thrombocytopenia in MDS: epidemiology, mechanisms, clinical consequences and novel therapeutic strategies.Long-Term Response in a Patient with del(5q) Myelodysplastic Syndrome Who Discontinued Lenalidomide and Obtained a Good Response and Tolerance to Rechallenge.Phase I combination trial of lenalidomide and azacitidine in patients with higher-risk myelodysplastic syndromes.Current therapy of myelodysplastic syndromesCombination of azacitidine and lenalidomide in myelodysplastic syndromes or acute myeloid leukemia-a wise liaison?How much? How frequent? How long? A clinical guide to new therapies in myelodysplastic syndromesExpanding role of lenalidomide in hematologic malignanciesInduction therapy and stem cell mobilization in patients with newly diagnosed multiple myeloma.Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes.The revolution of myelodysplastic syndromes.Efficacy and safety of lenalidomide in patients with myelodysplastic syndrome with chromosome 5q deletion.Analysis of the efficacy of lenalidomide in patients with intermediate-1 risk myelodysplastic syndrome without 5q deletion.Molecular predictors of response in patients with myeloid neoplasms treated with lenalidomide.Therapeutic modalities for patients with lower-risk myelodysplastic syndromes: current options and future directions.Management of lower-risk myelodysplastic syndromes: the art and evidence.Lenalidomide as a disease-modifying agent in patients with del(5q) myelodysplastic syndromes: linking mechanism of action to clinical outcomesUpdate on the pharmacotherapy for myelodysplastic syndromes.Darbepoetin alfa for anemia with myelodysplastic syndrome.Where Does Lenalidomide Fit in Non-del(5q) MDS?Lenalidomide use in myelodysplastic syndromes: Insights into the biologic mechanisms and clinical applications.Lenalidomide in patients with red blood cell transfusion-dependent myelodysplastic syndrome and del(5q): a single-centre "real-world" experience.A case of myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) successfully treated with lenalidomide.Efficacy of lenalidomide in an sAML patient with del 5q relapsing after reduced-intensity allogeneic stem cell transplantation performed in complete remission.Response to lenalidomide in myelodysplastic syndromes with del(5q): influence of cytogenetics and mutations.Is it time for 5-azacytidine combinations in high-risk myelodysplastic syndrome patients?Safety profile of lenalidomide in patients with lower-risk myelodysplastic syndromes without del(5q): results of a phase 3 trial.In vitro effects of perifosine, bortezomib and lenalidomide against hematopoietic progenitor cells from healthy donors.The 5q- syndrome: biology and treatment.Practical Strategies for Management of Lenalidomide-Associated Cytopenias in Myelodysplastic Syndromes With del(5q)Early platelet count kinetics has prognostic value in lower-risk myelodysplastic syndromes
P2860
Q26778754-774D351D-21D5-4D47-9A24-0173AE01763BQ33392683-AE2552AE-ACE5-44FD-B9C6-9837230181F1Q33398044-75466BE7-43E4-4950-AF00-CB7B03725D21Q33404600-995F64D5-7514-4958-855B-C15F8351B71DQ33408873-CAC01999-11CC-4E89-B48F-B3ECAF5F6050Q33427023-68C34D30-A4B2-4418-A33B-70532AB3C2C1Q33675946-10AB4223-BD70-409F-B6D7-011C945CB639Q33813750-53CD2E5C-C626-4AF3-9BDB-6372852D21F0Q34013796-E6D10769-476C-46C6-AA1C-9E0D537ED1C6Q34342944-7E54297F-5CB5-4E72-AC23-F960C16336EAQ35202854-1F958739-69F8-42FC-8761-AD2A86E4812AQ35592305-5BBA81B4-5335-4425-ADCC-178461D9A52AQ36014687-5EDC9411-95F9-4607-B758-356F3C098E7FQ36474572-24CC7E31-6B99-4A18-A055-8992C6D7C86AQ36612553-1C8D7A8E-7CDB-4738-BC5B-AF103A8BD519Q36612675-9933D589-A917-46D4-A3BF-9F361C84613AQ37207084-5644180C-6687-4F8C-A722-65CC543A6821Q37482287-918E1B8B-9FFD-4804-B4D1-69FE90177BD8Q37820432-CE2B0B73-3F58-4910-A959-3DE1792D86D4Q37858436-B0C4FD11-FCCC-4A9F-AA27-E1045A8AA565Q38135713-44F74982-A1F9-47E3-9ED7-4D4F5BB5EB79Q38235662-4760EE0C-4312-4E7A-A405-E3A10077081AQ38314705-FCCB153C-1436-49AE-BFD9-D950F8C46C20Q38546273-E0B3D753-064E-4FD2-AE0E-7C4616E4185FQ38758162-888E2B6C-9E05-4A28-953B-38517788976AQ41156034-F93C9FC1-9DC6-4D97-9CB6-5CA2497D062FQ42424824-0FA86543-CBCC-4D94-AB02-7647EFFC8BA5Q43283505-489D253C-5662-446D-80C2-C707632F2E44Q45155324-F3B27451-A141-48FD-B2AF-15F4BB7A8E04Q45419283-D72C2756-8F54-4218-9BB8-D8911CE819B2Q50095638-5DCE92EF-CFD9-4597-A356-43CD35476AA7Q50436837-2A398916-3F24-467F-AE72-D67AE5315D90Q54539679-D48745B4-C834-40FE-A80C-7B81031E45D1Q58585580-9095E92E-5068-4371-9F46-9B90C9F8E5E6Q58734670-DBB5C901-4CB9-4FE8-9C23-D4024065C8B7
P2860
Relationship of treatment-related cytopenias and response to lenalidomide in patients with lower-risk myelodysplastic syndromes.
description
2008 nî lūn-bûn
@nan
2008 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Relationship of treatment-rela ...... isk myelodysplastic syndromes.
@ast
Relationship of treatment-rela ...... isk myelodysplastic syndromes.
@en
type
label
Relationship of treatment-rela ...... isk myelodysplastic syndromes.
@ast
Relationship of treatment-rela ...... isk myelodysplastic syndromes.
@en
prefLabel
Relationship of treatment-rela ...... isk myelodysplastic syndromes.
@ast
Relationship of treatment-rela ...... isk myelodysplastic syndromes.
@en
P2093
P2860
P356
P1476
Relationship of treatment-rela ...... isk myelodysplastic syndromes.
@en
P2093
Alan F List
Aristotle A N Giagounidis
Jaroslaw P Maciejewski
Kenton Wride
Mikkael A Sekeres
Robert Knight
P2860
P304
P356
10.1200/JCO.2007.15.5770
P407
P577
2008-11-17T00:00:00Z